NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 912.9 DKK | -0.46% |
|
+3.36% | +30.77% |
| 05-16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| 05-16 | Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.77% | 595B | |
| +32.36% | 709B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B | |
| +0.45% | 163B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal
